First National Bank of Omaha Takes $6.60 Million Position in AbbVie Inc. $ABBV

First National Bank of Omaha bought a new stake in AbbVie Inc. (NYSE:ABBV) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 28,484 shares of the company’s stock, valued at approximately $6,595,000.

Other large investors have also recently bought and sold shares of the company. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie during the second quarter worth about $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the 2nd quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie during the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC purchased a new position in shares of AbbVie in the 2nd quarter valued at approximately $39,000. Finally, Access Investment Management LLC acquired a new position in shares of AbbVie in the second quarter valued at approximately $44,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the subject of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and set a $299.00 price target (up from $289.00) on shares of AbbVie in a report on Wednesday. BMO Capital Markets restated an “outperform” rating and set a $258.00 price objective on shares of AbbVie in a research report on Thursday, January 15th. JPMorgan Chase & Co. lifted their target price on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Finally, Scotiabank assumed coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $251.56.

AbbVie Stock Performance

AbbVie stock opened at $232.69 on Wednesday. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The firm has a market capitalization of $411.25 billion, a price-to-earnings ratio of 98.60, a P/E/G ratio of 0.81 and a beta of 0.35. The company has a 50 day moving average price of $223.93 and a 200 day moving average price of $221.63.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter last year, the firm posted $2.16 earnings per share. AbbVie’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.